DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of Claims
Claims 21-40 are currently pending and under examination. Claims 1-20 are canceled. As per the amendments filed on 09/11/2025, claims 21, 23, 30-31, and 37 are amended.
Response to Arguments
Applicant’s arguments, see Remarks page 9 (Claim Rejection Under 35 U.S.C. § 112(b)), filed 09/11/2025, with respect to the 35 U.S.C. § 112(b) rejection of claim 31 have been fully considered and are persuasive. Therefore, the rejection of claim 31 is withdrawn.
Applicant’s arguments, see Remarks pages 9-12 (Claim Rejections Under 35 U.S.C. § 103), filed 09/11/2025, with respect to the 35 U.S.C. § 103 rejections of claims 21-40 have been fully considered. Claims 21-22, 24-30, and 32-40 were rejected over Bolea (US PG Pub 2018/0078761 A1) in view of Boggs (US PG Pub 2011/0093032 A1) and claims 23 and 31 were rejected over Bolea in view of Boggs and Ahmad (US PG Pub 2015/0073232 A1). Applicant’s arguments are based on amendments to independent claims 21, 30 and 37.
Regarding the claim 21 limitation “the one or more motor points being at locations where each nerve axon of the one or more nerves terminates in at least one of the genioglossus muscle or the geniohyoid muscle, the stimulation electrodes being placed within 10 millimeters of a midline of the tongue,” Applicant argues:
In support of the rejection, such as for subject matter related to "motor points," the Office Action, on page 4, cited paragraph [0060] of Bolea stating that "([0060] - the stimulation of the hypoglossal nerves causes the tongue to protrude, meaning the electrodes are placed proximate to the protrusor muscle motor points." Applicant does not acquiesce that such disclosure of Bolea discloses the subject matter of claim 21 prior to amendment. Nevertheless, nothing in Bolea describes that the "delivery of the electrical energy [is] proximate ... to one or more motor points of the protrusor muscles of a patient, the one or more motor points being at locations where each nerve axon of the one or more nerves terminates in at least one of the genioglossus muscle or the geniohyoid muscle," much less where the stimulation electrodes used for delivery of the electrical energy are "placed within 10 millimeters of a midline of the tongue," as set forth in amended claim 21. (09/11/2025 Remarks, page 11)
This argument is persuasive. Regarding the pre-amendment limitation “which form protrusor muscles within a tongue, and proximate to one or more motor points of the protrusor muscles of a patient,” the Examiner interpreted Bolea as teaching this limitation with “[0060] – the stimulation of the hypoglossal nerves causes the tongue to protrude, meaning the electrodes are placed proximate to the protrusor muscle motor points” (06/12/2025 Non-Final Rejection, page 4). The amendment is seen as a more specific placement of the lead relative to the motor point. Therefore, the rejection of claim 21 is withdrawn. However, upon further consideration, a new ground(s) of rejection is made in view of Scheiner (US PG Pub 2017/0087360 A1), see “Claim Rejections - 35 USC § 103” section.
Regarding the claim 21 limitation “determining whether an apnea is likely to occur based on the one or more physiological parameters,” Applicant argues:
As noted above, in amended claim 21, the processing circuitry is configured to "determine whether an apnea is likely to occur based on the one or more physiological parameters." In support of the rejection, the Office Action cited paragraph [0161] of Bolea. In paragraph [0161], Bolea states that "the data may be used to turn stimulus on (e.g., when apnea or hypopnea events start occurring or when motion artifact is absent) or to turn stimulus off (e.g., when no apnea or hypopnea events are occurring over a present time period or when motion artifact is predominant)." Accordingly, in Bolea, the data is indicating that apnea or hypopnea events are starting to occur. In amended claim 21, the processing circuitry is determining whether an apnea is "likely to occur" ( emphasis added). Bolea does not provide disclosure of determining whether an apnea is likely to occur, as set forth in amended claim 21. Boggs and Ahmad have not been relied upon as disclosing any of the subject matter noted above that Bolea fails to disclose. Therefore, even if one of ordinary skill in the art, starting from Bolea, would have consulted Boggs or Ahmad, a point to which Applicant does not acquiesce, one of ordinary skill in the art would not have arrived at the combination of subject matter of claim 21. (09/11/2025 Remarks, pages 11-12)
The argument is not found to be persuasive. This could be interpreted as an extension of existing claim 21 limitation “determine an instance where (1) the tonal state of at least one of the genioglossus muscle or the geniohyoid muscle is a low tonal state, based on the sensed EMG, and (2) the apnea is likely to occur, based on the one or more physiological parameters.” The second part of the above limitation references Bolea [0161], where the Examiner states “[0161] - sensed data, such as the apnea hypopnea index derived from sensor outputs, is used to determine when an apnea event occurs” (06/12/2025 Non-Final Rejection, page 5). In [0161], Bolea states: “Generally, the extracted 378 waveform and event data may be used for therapy tracking, for stimulus titration, and/or for closed loop therapy control. For example, data indicative of apneas and hypopneas (or other events) may be stored by the INS 50 and/or telemetered to the patient controlled 40 […] The data may also be used to control stimulus in a closed loop fashion by, for example, increasing stimulus intensity during periods of increased apnea and hypopnea occurrence or decreasing stimulus intensity during periods of decreased apnea and hypopnea occurrence.” The Examiner is interpreting this passage as relating to Bolea associating detection of apnea or hypopnea events with an increased likelihood of additional apnea and hypopnea events occurring over a timeframe (and which should be addressed with changes to stimulation parameters). Bolea additionally describes this stimulation as decreasing the likelihood of apnea or hypopnea events occurring in [0042]. Therefore, the examiner does not find this argument persuasive and the same grounds of rejection for this limitation are maintained.
These arguments are used for the similar amendments to independent claims 30 and 37 and any dependent claims (“For at least these reasons, claim 21 recites novel and non-obvious subject matter. Applicant has amended claims 30 and 37 similar to claim 21. Claims 30 and 37 recite novel and non-obvious subject matter for similar reasons as claim 21 but may recite novel and non-obvious subject matter for additional reasons as well. The dependent claims recite novel and non-obvious subject matter at least by virtue of dependency upon respective independent claims but may recite novel and non-obvious subject matter for additional reasons as well. Applicant respectfully requests withdrawal of the rejection under 35 U.S.C. § 103 of claims 21-40” - 09/11/2025 Remarks, page 12). Therefore, the rejections of claims 22-40 are withdrawn based on the motor point argument discussed earlier. However, upon further consideration, a new ground(s) of rejection is made in view of Scheiner (US PG Pub 2017/0087360 A1), see “Claim Rejections - 35 USC § 103” section.
Summary: The 35 U.S.C. § 103 rejections for claims 21-40 are withdrawn. New 35 U.S.C. § 103 rejections for claims 21-22, 24-30, and 32-40 over Bolea in view of Boggs and Scheiner and claims 23 and 31 over Bolea in view of Boggs, Ahmad, and Scheiner are added (see “Claim Rejections - 35 USC § 103”).
Claim Rejections - 35 USC § 101
35 U.S.C. 101 reads as follows:
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
Section 33(a) of the America Invents Act reads as follows:
Notwithstanding any other provision of law, no patent may issue on a claim directed to or encompassing a human organism.
Claims 21-40 are rejected under 35 U.S.C. 101 and section 33(a) of the America Invents Act as being directed to or encompassing a human organism. See also Animals - Patentability, 1077 Off. Gaz. Pat. Office 24 (April 21, 1987) (indicating that human organisms are excluded from the scope of patentable subject matter under 35 U.S.C. 101). The amendments to claims 21, 30, and 37 contain the added limitation “the stimulation electrodes being placed within 10 millimeters of a midline of the tongue, ”which claims the electrodes and tongue. In order to provide a distinction between the device and the human organism, the claim could incorporate language equivalent to “configured to” with respect to the electrodes.
Claims 22-29, 31-36, and 38-40 are rejected for being dependent on rejected claims.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION —The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 21-29 and 37-40 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 21 is directed to a product (implantable neurostimulator with electrodes) and to a process (“the stimulation electrodes being placed within 10 millimeters of a midline of the tongue”), which renders the claim indefinite. MPEP 2173.05(p).II states:
A single claim which claims both an apparatus and the method steps of using the apparatus is indefinite under 35 U.S.C. 112(b) or pre-AIA 35 U.S.C. 112, second paragraph. See In re Katz Interactive Call Processing Patent Litigation, 639 F.3d 1303, 1318, 97 USPQ2d 1737, 1748-49 (Fed. Cir. 2011)
This rejection may be overcome by amending the claim to recite the apparatus configuration (e.g. electrodes “configured to”), rather than the actual method step.
Claim 37 is directed to a product (computer-readable storage medium) and to a process (“the stimulation electrodes being placed within 10 millimeters of a midline of the tongue”), which renders the claim indefinite (see MPEP 2173.05(p)). This rejection may be overcome by amending the claim to recite the apparatus configuration (e.g. electrodes “configured to”), rather than the actual method step.
Claims 22-29 and 38-40 are rejected for being dependent on rejected claims.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C.
103 are summarized as follows:
Determining the scope and contents of the prior art.
Ascertaining the differences between the prior art and the claims at issue
Resolving the level of ordinary skill in the pertinent art.
Considering objective evidence present in the application indicating obviousness or non-obviousness.
Claims 21-22, 24-30, and 32-40 are rejected under U.S.C 103 as being unpatentable over Bolea (US PG Pub 2018/0078761 A1, see previously cited) in view of Boggs II (US PG Pub 2011/0093032 A1, see IDS filed on 04/05/2023), to be referred to as Boggs, and Scheiner (US PG Pub 2017/0087360 A1, see “Notice of References Cited”).
Regarding Claim 21, Bolea discloses an implantable neuro stimulator (INS) system (Figure 4, [0046]) comprising:
• an electrical lead comprising one or more stimulation electrodes for delivery of electrical energy (Figure 5, [0049]) and one or more sensing electrodes configured to sense an electromyograph (EMG) ([0055] – respiration sensing lead can include an EMG)
wherein the electrical lead is configured for percutaneous implantation ([0091] – percutaneous implantation described) and placement of the one or more stimulation electrodes for delivery of the electrical energy proximate to one or more nerves of at least one of a genioglossus muscle or a geniohyoid muscle (Figure 12, [0068-0069] – genioglossus or geniohyoid muscles stimulated via stimulation of various points along the hypoglossal nerve), which form protrusor muscles within a tongue, and proximate to one or more motor points of the protrusor muscles of a patient ([0060] – the stimulation of the hypoglossal nerves causes the tongue to protrude, meaning the electrodes are placed proximate to the protrusor muscle motor points);
the one or more sensing electrodes are configured to sense the EMG proximate the protrusor muscles within the tongue ([0231] – “the intramuscular or surface electrodes may be used to measure genioglossus EMG activity, either with or without stimulation”); and
• a sensor configured to detect one or more physiological parameters ([0055] – different types of respiration sensors, both implanted and external, are discussed), and
• processing circuitry ([0047] – “The INS may contain a microprocessor and memory for storing and processing data and algorithms. Algorithms may be in the form of software and/or firmware, for example”) configured to:
determine a tonal state of at least one of the genioglossus muscle or the geniohyoid muscle that form the protrusor muscles within the tongue of the patient based on the sensed EMG ([0231] – “the intramuscular or surface electrodes may be used to measure genioglossus EMG activity, either with or without stimulation”, [0042 and 0227] - Note a low muscle tonal state, which is corrected by stimulation to the protrusor muscles like the genioglossus muscle, would be associated with reduced patency and collapse of the upper airway);
determining whether an apnea is likely to occur based on the one or more physiological parameters ([0161] - “Generally, the extracted 378 waveform and event data may be used for therapy tracking, for stimulus titration, and/or for closed loop therapy control. For example, data indicative of apneas and hypopneas (or other events) may be stored by the INS 50 and/or telemetered to the patient controlled 40 […] The data may also be used to control stimulus in a closed loop fashion by, for example, increasing stimulus intensity during periods of increased apnea and hypopnea occurrence or decreasing stimulus intensity during periods of decreased apnea and hypopnea occurrence.” The Examiner is interpreting this passage as relating to Bolea associating detection of apnea or hypopnea events with an increased likelihood of additional apnea and hypopnea events occurring over a timeframe (and which should be addressed with changes to stimulation parameters). Bolea additionally describes this stimulation as decreasing the likelihood of apnea or hypopnea events occurring in [0042]);
determine an instance where (1) the tonal state of at least one of the genioglossus muscle or the geniohyoid muscle is a low tonal state, based on the sensed EMG ([0231] – genioglossus
EMG activity measured, [0246] – the tonal state of the genioglossus or different muscles in the upper airway is assessed, along with sensing apnea/hypopnea, in order to determine the stimulation needed to establish patency), and (2) an apnea is likely to occur, based on the one or more physiological parameters ([0161] - sensed data, such as the apnea hypopnea index derived from sensor outputs, is used to determine when an apnea event occurs); and
control a timing of when electrical energy is delivered to the one or more stimulation electrodes for delivery of the electrical energy based on the determined instance ([0242] – determination of stimulation pattern based on EMG feedback, [0161] – the determination of an apnea event, with physiologic parameters, can be used in closed-loop therapy stimulation control).
Bolea discloses “stimulus may be delivered to one or more of a variety of nerve sites to activate one muscle or muscle groups controlling patency of the upper airway” ([0042]) where “as an alternative or in addition, the nerve cuff electrode 64 may be replaced with an intramuscular electrode and placed directly in the musculature affecting patency of the upper airway […] nerve electrode may be attached to a specific branch of a nerve innervating the desired muscle(s), or may be attached to a proximal trunk of the nerve in which a specific fascicle innervating the desired muscle(s) is targeted by steering the stimulus with multiple electrodes” ([0049]). Therefore, any location between the nerve innervating one or multiple muscles and the muscle itself could be stimulated by the implanted electrode. This is interpreted as addressing the limitation “the one or more motor points being at locations where each nerve axon of the one or more nerves terminates in at least one of the genioglossus muscle or the geniohyoid muscle.” However, Bolea does not disclose “without attaching” in the limitation stimulation electrodes for delivery of the electrical energy proximate, and without attaching, to one or more nerves of at least one of a genioglossus muscle or a geniohyoid muscle. Additional Bolea does not disclose the stimulation electrodes being placed within 10 millimeters of a midline of the tongue.
Boggs, in the same field of endeavor of electrical stimulation for stimulating airway muscles (Abstract, [0045] – gives examples of airway muscles stimulated), teaches an electrical stimulation which can be placed a set distance from a target nerve ([0043] – “Other types of electrical stimulation may include stimulation delivered by electrode contact(s) not in direct contact with the nerve but that are near or some distance away from the nerve”). Boggs states that less invasive placement procedures “provide[s] many benefits. For instance, such introduction minimizes procedure time, tissue damage, and recovery time” ([0043]).
It would have been obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to alter Bolea’s nerve cuff for placement around nerves innervating airway muscles by incorporating the electrical field electrode which can stimulate nerves innervating airway muscles at a distance. This would have been obvious because both Bolea and Boggs provide stimulation to improve airway patency during sleep apneas and Boggs provides a solution/improvement which mitigates mechanical damage from installation around the nerve structure. Therefore, a person of ordinary skill in the art would be motivated to improve the system of Bolea by incorporating the electrical field electrode which can stimulate nerves innervating airway muscles at a distance.
Scheiner, in the same field of endeavor of electrical stimulation for stimulating airway muscles ([0002-0003]), teaches electrical stimulation electrodes 46ab and 24 (assumed to be 44ab as shown in Figure 2) being placed 4 mm and 5.5 mm from the midline of the tongue ([0094]). MPEP 2144.05 states “In the case where the claimed ranges ‘overlap or lie inside ranges disclosed by the prior art’ a prima facie case of obviousness exists.” There is no evidence of an “unexpected result or criticality” on the analysis from the discussed range interpretations as it pertains to values within 10 mm. The electrodes are situated to stimulate either neural tissue or muscles directly ([0077]), such as the hypoglossal nerve ([0077]), genioglossus muscle ([0078]), or geniohyoid muscle ([0081]).
It would have been obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to have modified the stimulation nerve cuff in Bolea with the placement relative to the tongue in Scheiner. Given the variety of electrode placement positions in Bolea for stimulating the nerves and muscles, it would have been obvious to try the 4 mm and 5.5 mm electrode placement away from the tongue’s midline in Scheiner. A person of ordinary skill in the art would have a reasonable expectation of successfully using electrode position in Scheiner with the device in Bolea.
Therefore, Claim 21 is obvious over Bolea in view of Boggs and Scheiner.
Regarding Claim 22, the implantable neuro stimulator system according to claim 21 is obvious over Bolea in view of Boggs and Scheiner, as indicated hereinabove. Bolea further discloses a pulse generator, wherein the pulse generator comprises the processing circuitry ([0047] – processor circuits and functions are contained within the implantable neurostimulator body for both stimulation and sensing).
Therefore, Claim 22 is obvious over Bolea in view of Boggs and Scheiner.
Regarding Claim 24, the implantable neuro stimulator system according to claim 21 is obvious over Bolea in view of Boggs and Scheiner, as indicated hereinabove. Bolea further discloses:
• a communications telemetry module (CTM) ([0047] – “The INS may contain a microprocessor and memory for storing and processing data and algorithms”) configured to receive data collected by the sensor and data related to the delivery of electrical energy ([0047] – “modified for the present clinical application in terms of stimulation signal parameters, respiratory signal processing, trigger algorithm, patient control, physician programming, etc.”); and
• an external programmer (physician programmer 30) in communication with the CTM and configured to display a user interface (Figure 1, [0043] – a display screen is shown for a programmer computer) that includes one or more of the data collected by the sensor ([0161] – “For example, data indicative of apneas and hypopneas (or other events) may be stored by the INS 50 and/or telemetered to the patient controlled 40. The data may be subsequently transmitted or downloaded to the physician programmer 30”) and the data related to the delivery of the electrical energy ([0034] – the physician programmer is used to adjust the electrical parameters in the stimulator: “the physician programmer 30 may comprise a computer 32 configured to control and program the INS 50 via a wireless link to a
programming wand 34”).
Therefore, Claim 24 is obvious over Bolea in view of Boggs and Scheiner.
Regarding Claim 25, the implantable neuro stimulator system according to claim 21 is obvious over Bolea in view of Boggs and Scheiner, as indicated hereinabove. Bolea further discloses wherein the processing circuitry is configured to adjust parameters of the electrical energy based on the tonal state of at least one of the genioglossus muscle or the geniohyoid muscle ([0242] – determination of stimulation pattern based on EMG feedback: “The system described above may modulate electrical stimulation intensity proportion based on electromyogram (EMG) feedback from the muscles in the upper airway being stimulated or others in the area. This feedback may be used to determine the correct proportion of stimulation between protruders and retruders”). Genioglossus EMG is explicitly measured ([0231]) and a low tonal state would be associated with reduced patency and collapse of the upper airway ([0042]).
Therefore, Claim 25 is obvious over Bolea in view of Boggs and Scheiner.
Regarding Claim 26, the implantable neuro stimulator system according to claim 21 is obvious over Bolea in view of Boggs and Scheiner, as indicated hereinabove. Bolea further discloses wherein the one or more physiological parameters include one or more of motion data ([0139-0140] – motion artifact suggests motion can be measured as a parameter in a similar fashion as noise from the heart in the impedance signal), heart rate data, respiration rate data, or posture data ([0172] – “The selection of the algorithm can be made automatically by the INS based on: patient sleep position (position sensor), heart rate (detectable through the impedance measuring system) or respiration rate”). Posture data can encompass both sleep position and whether the patient is standing or sitting ([0247]). Bolea does not disclose electrocardiogram data or blood-oxygen saturation data. Only one of the listed parameters is interpreted as required based on the claim language.
Therefore, Claim 26 is obvious over Bolea in view of Boggs and Scheiner.
Regarding Claim 27, the INS system according to claim 21 is obvious over Bolea in view of Boggs and Scheiner, as indicated hereinabove. Bolea further discloses wherein the processing circuitry is configured to calculate an Apnea-Hypopnea Index (AHI) value ([0061, 0161]). Bolea does not explicitly discuss the computation of a Respiration Disturbance Index (RDI) value, total sleep time, sleep efficiency value, or therapeutic efficiency based on the one or more physiological parameters. An RDI value was used as a computational tool when Bolea discusses prior art ([0006]). Sleep time vs. awake time is measured in Bolea ([0148]), but total sleep time is not disclosed as a parameter. Only one of the listed parameters is interpreted as required based on the claim language.
Therefore, Claim 27 is obvious over Bolea in view of Boggs and Scheiner.
Regarding Claim 28, the implantable neuro stimulator system according to claim 21 is obvious over Bolea in view of Boggs and Scheiner, as indicated hereinabove. Bolea further discloses wherein the processing circuitry is configured to:
• analyze electronic medical record (EMR) data of a population ([0163] – historical sensor data and settings stored in the memory are analyzed: “The sensors and device memory are the sources of real-time data and historical fiducial data which the current algorithm uses to generate a stimulation trigger signal. The data 484 utilized in implementing the algorithm may include patient specific data derived from a sleep study (i.e., PSG data), data from titrating the system post implantation, and historic and real-time respiratory data including respiratory and event fiducials”). The historical data and stored stimulation parameters could be considered an electronic medical record.
• identify one or more parameters for adjustment in a therapy delivery program for the delivery of the electrical energy based on the analysis of the EMR data ([0165] – “modification of the default algorithm may require a reference datum. The reference datum may be the estimated onset for past respiratory cycles … This estimation of inspiratory onset for previous respiratory cycles may be specific to person, sensor location, sleep stage, sleep position, or a variety of other factors”);
• adjust the one or more parameters of the therapy delivery program ([0164] – “the current algorithm may be derived from real-time and historical data to yield a stimulation trigger signal 488 … The processes 486 utilized in implementing the algorithm may include providing a default algorithm preprogrammed in the INS, patient controller or physician programmer, modifying the default algorithm, and deriving a current algorithm used to generate a trigger signal 488”).
Therefore, Claim 28 is obvious over Bolea in view of Boggs and Scheiner.
Regarding Claim 29, the implantable neuro stimulator system according to claim 21 is obvious over Bolea in view of Boggs and Scheiner, as indicated hereinabove. Bolea further discloses wherein at least one of the one or more stimulation electrodes and at least one of the one or more sensing electrodes is the same electrode ([0251] – stimulation and sensing functions on the same electrodes/leads are discussed with sensing signals near the stimulated muscles).
Therefore, Claim 29 is obvious over Bolea in view of Boggs and Scheiner.
Regarding Claim 30, Bolea discloses a method ([0002]) comprising:
• receiving information of an electromyograph (EMG) sensed proximate to protrusor muscles within a tongue of a patient with one or more sensing electrodes of an electrical lead configured to sense the EMG ([0242] – EMG sensed for tongue protrusor muscles of the upper airway), wherein the electrical lead comprises one or more stimulation electrodes for delivery of electrical energy (Figure 5, [0049]) and the one or more sensing electrodes ([0055] – respiration sensing lead can include an EMG), and
• wherein the electrical lead is configured for percutaneous implantation ([0091] – percutaneous implantation described) and placement of the one or more stimulation electrodes proximate to one or more nerves of at least one of a genioglossus muscle or a geniohyoid muscle (Figure 12, [0068-0069] – genioglossus or geniohyoid muscles stimulated via stimulation of various points along the hypoglossal nerve), which form the protrusor muscles within the tongue, and proximate to one or more motor points of the protrusor muscles of the patient ([0060] – the stimulation of the hypoglossal nerves causes the tongue to protrude, meaning the electrodes are placed proximate to the protrusor muscle motor points);
• receiving information of one or more physiological parameters ([0055] – different types of respiration sensors, both implanted and external, are discussed);
• determining a tonal state of at least one of the genioglossus muscle or the geniohyoid muscle that form the protrusor muscles within the tongue of the patient based on the sensed EMG ([0231] – “the intramuscular or surface electrodes may be used to measure genioglossus EMG activity, either with or without stimulation”, [0042 and 0227] - Note a low muscle tonal state, which is corrected by stimulation to the protrusor muscles like the genioglossus muscle, would be associated with reduced patency and collapse of the upper airway);
• determining whether an apnea is likely to occur based on the one or more physiological parameters ([0161] - “Generally, the extracted 378 waveform and event data may be used for therapy tracking, for stimulus titration, and/or for closed loop therapy control. For example, data indicative of apneas and hypopneas (or other events) may be stored by the INS 50 and/or telemetered to the patient controlled 40 […] The data may also be used to control stimulus in a closed loop fashion by, for example, increasing stimulus intensity during periods of increased apnea and hypopnea occurrence or decreasing stimulus intensity during periods of decreased apnea and hypopnea occurrence.” The Examiner is interpreting this passage as relating to Bolea associating detection of apnea or hypopnea events with an increased likelihood of additional apnea and hypopnea events occurring over a timeframe (and which should be addressed with changes to stimulation parameters). Bolea additionally describes this stimulation as decreasing the likelihood of apnea or hypopnea events occurring in [0042]);
• determining an instance where (1) the tonal state of at least one of the genioglossus muscle or the geniohyoid muscle is a low tonal state, based on the sensed EMG ([0231] – genioglossus EMG activity measured, [0246] – the tonal state of the genioglossus or different muscles in the upper airway is assessed, along with sensing apnea/hypopnea, in order to determine the stimulation needed to establish patency) and (2) an apnea is likely to occur, based on the one or more physiological parameters ([0161] - sensed data, such as the apnea hypopnea index derived from sensor outputs, is used to determine when an apnea event occurs); and
• controlling a timing of when electrical energy is delivered to the one or more stimulation electrodes for delivery of the electrical energy based on the determined instance ([0242] – determination of stimulation pattern based on EMG feedback, [0161] – the determination of an apnea event, with physiologic parameters, can be used in closed-loop therapy stimulation control).
Bolea discloses “stimulus may be delivered to one or more of a variety of nerve sites to activate one muscle or muscle groups controlling patency of the upper airway” ([0042]) where “as an alternative or in addition, the nerve cuff electrode 64 may be replaced with an intramuscular electrode and placed directly in the musculature affecting patency of the upper airway […] nerve electrode may be attached to a specific branch of a nerve innervating the desired muscle(s), or may be attached to a proximal trunk of the nerve in which a specific fascicle innervating the desired muscle(s) is targeted by steering the stimulus with multiple electrodes” ([0049]). Therefore, any location between the nerve innervating one or multiple muscles and the muscle itself could be stimulated by the implanted electrode. This is interpreted as addressing the limitation “the one or more motor points being at locations where each nerve axon of the one or more nerves terminates in at least one of the genioglossus muscle or the geniohyoid muscle.” Bolea does not disclose “without attaching” in the limitation stimulation electrodes for delivery of the electrical energy proximate, and without attaching, to one or more nerves of at least one of a genioglossus muscle or a geniohyoid muscle. Additional Bolea does not disclose the stimulation electrodes being placed within 10 millimeters of a midline of the tongue
Boggs, in the same field of endeavor of electrical stimulation for stimulating airway muscles (Abstract, [0045] – gives examples of muscles stimulated), teaches an electrical stimulation which can be placed a set distance from a target nerve ([0043] – “Other types of electrical stimulation may include stimulation delivered by electrode contact(s) not in direct contact with the nerve but that are near or some distance away from the nerve”). Boggs states that less invasive placement procedures “provide[s] many benefits. For instance, such introduction minimizes procedure time, tissue damage, and recovery time” ([0043]).
It would have been obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to alter Bolea’s method for placement around nerves innervating airway muscles by incorporating the electrical field electrode which can stimulate nerves innervating airway muscles at a distance. This would have been obvious because both Bolea and Boggs provide stimulation to improve airway patency during sleep apneas and Boggs provides a solution/improvement which mitigates mechanical damage from installation around the nerve structure. Therefore, a person of ordinary skill in the art would be motivated to improve the method of Bolea by incorporating the electrical field electrode which can stimulate nerves innervating airway muscles at a distance.
Scheiner, in the same field of endeavor of electrical stimulation for stimulating airway muscles ([0002-0003]), teaches electrical stimulation electrodes 46ab and 24 (assumed to be 44ab as shown in Figure 2) being placed 4 mm and 5.5 mm from the midline of the tongue ([0094]). MPEP 2144.05 states “In the case where the claimed ranges ‘overlap or lie inside ranges disclosed by the prior art’ a prima facie case of obviousness exists.” There is no evidence of an “unexpected result or criticality” on the analysis from the discussed range interpretations as it pertains to values within 10 mm. The electrodes are situated to stimulate either neural tissue or muscles directly ([0077]), such as the hypoglossal nerve ([0077]), genioglossus muscle ([0078]), or geniohyoid muscle ([0081]).
It would have been obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to have modified the stimulation nerve cuff in Bolea with the placement relative to the tongue in Scheiner. Given the variety of electrode placement positions in Bolea for stimulating the nerves and muscles, it would have been obvious to try the 4 mm and 5.5 mm electrode placement away from the tongue’s midline in Scheiner. A person of ordinary skill in the art would have a reasonable expectation of successfully using electrode position in Scheiner with the method in Bolea.
Therefore, Claim 30 is obvious over Bolea in view of Boggs and Scheiner
Regarding Claim 32, the method according to claim 30 is obvious over Bolea in view of Boggs and Scheiner, as indicated hereinabove. Bolea further discloses adjusting parameters of the electrical energy based on the tonal state of at least one of the genioglossus muscle or the geniohyoid muscle ([0242] – determination of stimulation pattern based on EMG feedback: “The system described above may modulate electrical stimulation intensity proportion based on electromyogram (EMG) feedback from the muscles in the upper airway being stimulated or others in the area. This feedback may be used to determine the correct proportion of stimulation between protruders and retruders”). Genioglossus EMG is explicitly measured ([0231]) and a low tonal state would be associated with reduced patency and collapse of the upper airway ([0042]).
Therefore, Claim 32 is obvious over Bolea in view of Boggs and Scheiner
Regarding Claim 33, the method according to claim 30 is obvious over Bolea in view of Boggs and Scheiner, as indicated hereinabove. Bolea further discloses wherein the one or more physiological parameters include one or more of the one or more physiological parameters include one or more of motion data ([0139-0140] – motion artifact suggests motion can be measured as a parameter in a similar fashion as noise from the heart in the impedance signal), heart rate data, respiration rate data, or posture data ([0172] – “The selection of the algorithm can be made automatically by the INS based on: patient sleep position (position sensor), heart rate (detectable through the impedance measuring system) or respiration rate”). Posture data can encompass both sleep position and whether the patient is standing or sitting ([0247]). Bolea does not disclose electrocardiogram data or blood-oxygen saturation data. Only one of the listed parameters is interpreted as required based on the claim language.
Therefore, Claim 33 is obvious over Bolea in view of Boggs and Scheiner
Regarding Claim 34, the method according to claim 30 is obvious over Bolea in view of Boggs and Scheiner, as indicated hereinabove. Bolea further discloses calculating an Apnea-Hypopnea Index (AHI) value ([0061, 0161]). Bolea does not explicitly discuss the computation of a Respiration Disturbance Index (RDI) value, total sleep time, sleep efficiency value, or therapeutic efficiency based on the one or more physiological parameters. An RDI value was used as a computational tool when Bolea discusses prior art ([0006]). Sleep time vs. awake time is measured in Bolea ([0148]), but total sleep time is not disclosed as a parameter. Only one of the listed parameters is interpreted as required based on the claim language.
Therefore, Claim 34 is obvious over Bolea in view of Boggs and Scheiner
Regarding Claim 35, the method according to claim 30 is obvious over Bolea in view of Boggs and Scheiner, as indicated hereinabove. Bolea further discloses:
• analyzing electronic medical record (EMR) data of a population ([0163] – historical sensor data and settings stored in the memory are analyzed: “The sensors and device memory are the sources of real-time data and historical fiducial data which the current algorithm uses to generate a stimulation trigger signal. The data 484 utilized in implementing the algorithm may include patient specific data derived from a sleep study (i.e., PSG data), data from titrating the system post implantation, and historic and real-time respiratory data including respiratory and event fiducials”). The historical data and stored stimulation parameters could be considered an electronic medical record.
• identifying one or more parameters for adjustment in a therapy delivery program for the delivery of the electrical energy based on the analysis of the EMR data ([0165] – “modification of the default algorithm may require a reference datum. The reference datum may be the estimated onset for past respiratory cycles … This estimation of inspiratory onset for previous respiratory cycles may be specific to person, sensor location, sleep stage, sleep position, or a variety of other factors”); and
• adjusting the one or more parameters of the therapy delivery program ([0164] – “the current algorithm may be derived from real-time and historical data to yield a stimulation trigger signal 488 … The processes 486 utilized in implementing the algorithm may include providing a default algorithm preprogrammed in the INS, patient controller or physician programmer, modifying the default algorithm, and deriving a current algorithm used to generate a trigger signal 488”).
Therefore, Claim 35 is obvious over Bolea in view of Boggs and Scheiner
Regarding Claim 36, the method according to claim 30 is obvious over Bolea in view of Boggs and Scheiner, as indicated hereinabove. Bolea further discloses wherein at least one of the one or more stimulation electrodes and at least one of the one or more sensing electrodes is the same electrode ([0251] – stimulation and sensing functions on the same electrodes/leads are discussed with sensing signals near the stimulated muscles).
Therefore, Claim 36 is obvious over Bolea in view of Boggs and Scheiner
Regarding Claim 37, Bolea discloses a computer-readable storage medium storing instructions thereon that when executed cause one or more processors ([0047] – “The INS may contain a microprocessor and memory for storing and processing data and algorithms. Algorithms may be in the form of software and/or firmware, for example”) to:
• receive information of an electromyograph (EMG) sensed proximate to protrusor muscles within a tongue of a patient with one or more sensing electrodes of an electrical lead configured to sense the EMG ([0242] – EMG sensed for tongue protrusor muscles of the upper airway), wherein the electrical lead comprises one or more stimulation electrodes for delivery of electrical energy (Figure 5, [0049]) and the one or more sensing electrodes ([0055] – respiration sensing lead can include an EMG), and
• wherein the electrical lead is configured for percutaneous implantation ([0091] – percutaneous implantation described) and placement of the one or more stimulation electrodes proximate to one or more nerves of at least one of a genioglossus muscle or a geniohyoid muscle (Figure 12, [0068-0069] – genioglossus or geniohyoid muscles stimulated via stimulation of various points along the hypoglossal nerve), which form the protrusor muscles within the tongue, and proximate to one or more motor points of the protrusor muscles of the patient ([0060] – the stimulation of the hypoglossal nerves causes the tongue to protrude, meaning the electrodes are placed proximate to the protrusor muscle motor points);
• receive information of one or more physiological parameters ([0055] – different types of respiration sensors, both implanted and external, are discussed);
• determine a tonal state of at least one of the genioglossus muscle or the geniohyoid muscle that form the protrusor muscles within the tongue of the patient based on the sensed EMG ([0231] – “the intramuscular or surface electrodes may be used to measure genioglossus EMG activity, either with or without stimulation”, [0042 and 0227] - Note a low muscle tonal state, which is corrected by stimulation to the protrusor muscles like the genioglossus muscle, would be associated with reduced patency and collapse of the upper airway);
• determine whether an apnea is likely to occur based on the one or more physiological parameters ([0161] - “Generally, the extracted 378 waveform and event data may be used for therapy tracking, for stimulus titration, and/or for closed loop therapy control. For example, data indicative of apneas and hypopneas (or other events) may be stored by the INS 50 and/or telemetered to the patient controlled 40 […] The data may also be used to control stimulus in a closed loop fashion by, for example, increasing stimulus intensity during periods of increased apnea and hypopnea occurrence or decreasing stimulus intensity during periods of decreased apnea and hypopnea occurrence.” The Examiner is interpreting this passage as relating to Bolea associating detection of apnea or hypopnea events with an increased likelihood of additional apnea and hypopnea events occurring over a timeframe (and which should be addressed with changes to stimulation parameters). Bolea additionally describes this stimulation as decreasing the likelihood of apnea or hypopnea events occurring in [0042]);
• determine an instance where (1) the tonal state of at least one of the genioglossus muscle or the geniohyoid muscle is a low tonal state, based on the sensed EMG ([0231] – genioglossus EMG activity measured, [0246] – the tonal state of the genioglossus or different muscles in the upper airway is assessed, along with sensing apnea/hypopnea, in order to determine the stimulation needed to establish patency) and (2) an apnea is likely to occur, based on the one or more physiological parameters ([0161] - sensed data, such as the apnea hypopnea index derived from sensor outputs, is used to determine when an apnea event occurs); and
• control a timing of when electrical energy is delivered to the one or more stimulation electrodes for delivery of the electrical energy based on the determined instance ([0242] – determination of stimulation pattern based on EMG feedback, [0161] – the determination of an apnea event, with physiologic parameters, can be used in closed-loop therapy stimulation control).
Bolea discloses “stimulus may be delivered to one or more of a variety of nerve sites to activate one muscle or muscle groups controlling patency of the upper airway” ([0042]) where “as an alternative or in addition, the nerve cuff electrode 64 may be replaced with an intramuscular electrode and placed directly in the musculature affecting patency of the upper airway […] nerve electrode may be attached to a specific branch of a nerve innervating the desired muscle(s), or may be attached to a proximal trunk of the nerve in which a specific fascicle innervating the desired muscle(s) is targeted by steering the stimulus with multiple electrodes” ([0049]). Therefore, any location between the nerve innervating one or multiple muscles and the muscle itself could be stimulated by the implanted electrode. This is interpreted as addressing the limitation “the one or more motor points being at locations where each nerve axon of the one or more nerves terminates in at least one of the genioglossus muscle or the geniohyoid muscle.” Bolea does not disclose “without attaching” in the limitation stimulation electrodes for delivery of the electrical energy proximate, and without attaching, to one or more nerves of at least one of a genioglossus muscle or a geniohyoid muscle. Additional Bolea does not disclose the stimulation electrodes being placed within 10 millimeters of a midline of the tongue.
Boggs, in the same field of endeavor of electrical stimulation for stimulating airway muscles (Abstract, [0045] – gives examples of muscles stimulated), teaches an electrical stimulation which can be placed a set distance from a target nerve ([0043] – “Other types of electrical stimulation may include stimulation delivered by electrode contact(s) not in direct contact with the nerve but that are near or some distance away from the nerve”). Boggs states that less invasive placement procedures “provide[s] many benefits. For instance, such introduction minimizes procedure time, tissue damage, and recovery time” ([0043]).
It would have been obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to alter Bolea’s nerve cuff for placement around nerves innervating airway muscles by incorporating the electrical field electrode which can stimulate nerves innervating airway muscles at a distance. This would have been obvious because both Bolea and Boggs provide stimulation to improve airway patency during sleep apneas and Boggs provides a solution/improvement which mitigates mechanical damage from installation around the nerve structure. Therefore, a person of ordinary skill in the art would be motivated to improve the system of Bolea by incorporating the electrical field electrode which can stimulate nerves innervating airway muscles at a distance.
Scheiner, in the same field of endeavor of electrical stimulation for stimulating airway muscles ([0002-0003]), teaches electrical stimulation electrodes 46ab and 24 (assumed to be 44ab as shown in Figure 2) being placed 4 mm and 5.5 mm from the midline of the tongue ([0094]). MPEP 2144.05 states “In the case where the claimed ranges ‘overlap or lie inside ranges disclosed by the prior art’ a prima facie case of obviousness exists.” There is no evidence of an “unexpected result or criticality” on the analysis from the discussed range interpretations as it pertains to values within 10 mm. The electrodes are situated to stimulate either neural tissue or muscles directly ([0077]), such as the hypoglossal nerve ([0077]), genioglossus muscle ([0078]), or geniohyoid muscle ([0081]).
It would have been obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to have modified the stimulation nerve cuff in Bolea with the placement relative to the tongue in Scheiner. Given the variety of electrode placement positions in Bolea for stimulating the nerves and muscles, it would have been obvious to try the 4 mm and 5.5 mm electrode placement away from the tongue’s midline in Scheiner. A person of ordinary skill in the art would have a reasonable expectation of successfully using electrode position in Scheiner with the device in Bolea.
Therefore, Claim 37 is obvious over Bolea in view of Boggs and Scheiner.
Regarding Claim 38, the computer-readable storage medium storing instructions according to claim 37 is obvious over Bolea in view of Boggs and Scheiner, as indicated hereinabove. Bolea further discloses instructions that cause the one or more processors to adjust parameters of the electrical energy based on the tonal state of at least one of the genioglossus muscle or the geniohyoid muscle ([0242] – determination of stimulation pattern based on EMG feedback: “The system described above may modulate electrical stimulation intensity proportion based on electromyogram (EMG) feedback from the muscles in the upper airway being stimulated or others in the area. This feedback may be used to determine the correct proportion of stimulation between protruders and retruders”). Genioglossus EMG is explicitly measured ([0231]) and a low tonal state would be associated with reduced patency and collapse of the upper airway ([0042]).
Therefore, Claim 38 is obvious over Bolea in view of Boggs and Scheiner
Regarding Claim 39, the computer-readable storage medium storing instructions according to claim 37 is obvious over Bolea in view of Boggs and Scheiner, as indicated hereinabove. Bolea further discloses wherein the one or more physiological parameters include one or more of motion data ([0139-0140] – motion artifact suggests motion can be measured as a parameter in a similar fashion as noise from the heart in the impedance signal), heart rate data, respiration rate data, or posture data ([0172] – “The selection of the algorithm can be made automatically by the INS based on: patient sleep position (position sensor), heart rate (detectable through the impedance measuring system) or respiration rate”). Posture data can encompass both sleep position and whether the patient is standing or sitting ([0247]). Bolea does not disclose electrocardiogram data or blood-oxygen saturation data. Only one of the listed parameters is interpreted as required based on the claim language.
Therefore, Claim 39 is obvious over Bolea in view of Boggs and Scheiner
Regarding Claim 40, the computer-readable storage medium storing instructions according to claim 37 is obvious over Bolea in view of Boggs and Scheiner, as indicated hereinabove. Bolea further discloses instructions that cause the one or more processors to calculate an Apnea-Hypopnea Index (AHI) value ([0061, 0161]). Bolea does not explicitly discuss the computation of a Respiration Disturbance Index (RDI) value, total sleep time, sleep efficiency value, or therapeutic efficiency based on the one or more physiological parameters. An RDI value was used as a computational tool when Bolea discusses prior art ([0006]). Sleep time vs. awake time is measured in Bolea ([0148]), but total sleep time is not disclosed as a parameter. Only one of the listed parameters is interpreted as required based on the claim language.
Therefore, Claim 40 is obvious over Bolea in view of Boggs and Scheiner
Claims 23 and 31 are rejected under U.S.C 103 as being unpatentable over Bolea (US PG Pub 2018/0078761 A1, see previously cited) in view of Boggs II (US PG Pub 2011/0093032 A1, see IDS filed on 04/05/2023), to be referred to as Boggs, Ahmad (US PG Pub 2015/0073232 A1, see previously cited), and Scheiner (US PG Pub 2017/0087360 A1, see “Notice of References Cited”).
Regarding Claim 23, the implantable neuro stimulator system according to claim 21 is obvious over Bolea in view of Boggs and Scheiner, as indicated hereinabove. Bolea discloses a processing circuitry ([0047] – “The INS may contain a microprocessor and memory for storing and processing data and algorithms. Algorithms may be in the form of software and/or firmware, for example”) configured to:
determine a tonal state of at least one of the genioglossus muscle or the geniohyoid muscle that form the protrusor muscles within the tongue of the patient based on the sensed EMG ([0231] – “the intramuscular or surface electrodes may be used to measure genioglossus EMG activity, either with or without stimulation”, [0042 and 0227] - Note a low muscle tonal state, which is corrected by stimulation to the protrusor muscles like the genioglossus muscle, would be associated with reduced patency and collapse of the upper airway);
determine whether an apnea is likely to occur based on the one or more physiological parameters ([0161] - “Generally, the extracted 378 waveform and event data may be used for therapy tracking, for stimulus titration, and/or for closed loop therapy control. For example, data indicative of apneas and hypopneas (or other events) may be stored by the INS 50 and/or telemetered to the patient controlled 40 […] The data may also be used to control stimulus in a closed loop fashion by, for example, increasing stimulus intensity during periods of increased apnea and hypopnea occurrence or decreasing stimulus intensity during periods of decreased apnea and hypopnea occurrence.” The Examiner is interpreting this passage as relating to Bolea associating detection of apnea or hypopnea events with an increased likelihood of additional apnea and hypopnea events occurring over a timeframe (and which should be addressed with changes to stimulation parameters). Bolea additionally describes this stimulation as decreasing the likelihood of apnea or hypopnea events occurring in [0042]);
determine an instance where (1) the tonal state of at least one of the genioglossus muscle or the geniohyoid muscle is a low tonal state, based on the sensed EMG ([0231] – genioglossus EMG activity measured, [0246] – the tonal state of the genioglossus or different muscles in the upper airway is assessed, along with sensing apnea/hypopnea, in order to determine the stimulation needed to establish patency) and (2) an apnea is likely to occur, based on the one or more physiological parameters ([0161] - sensed data, such as the apnea hypopnea index derived from sensor outputs, is used to determine when an apnea event occurs); and
control a timing of when electrical energy is delivered to the one or more stimulation electrodes for delivery of the electrical energy based on the determined instance ([0242] – determination of stimulation pattern based on EMG feedback, [0161] – the determination of an apnea event, with physiologic parameters, can be used in closed-loop therapy stimulation control).
Bolea does not disclose the processing circuity uses an artificial intelligence (AI) engine configured for these functions.
Ahmad, in the same field of endeavor of stimulation of respiratory muscles during an apnea event ([0013]), teaches muscle tone via EMG or other physiologic parameters can be used to discern whether an apnea event is occurring ([0071]). The microprocessor can be used to apply stimulation upon detection and adjust stimulation intensity based on sensed data ([0131]). Ahmad also teaches the use of an AI engine to adjust stimulation based on inputs from sensors ([0100] – “Optionally, the therapeutic device and/or the associated external device will have self-learning capability to adjust stimulation levels and/or timing to the individual patient and the ambient”; [0186] – “The diagnostic and therapeutic devices are each a self-learning device uses artificial intelligence to adopt and adjust to the circumstances in which it is used. Each device adjusts itself to changes in the environmental conditions during the test as well as the changes in patient/user's conditions. Built in artificial intelligence also keeps tracks of the trends and historic values”).
It would have been obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to alter Bolea’s system for determining stimulation parameters via sensed data by incorporating the AI program for determining stimulation parameters via sensed data in Ahmad. This would have been obvious because both Bolea and Ahmad provide stimulation to improve airway patency during detected sleep apneas and Ahmad provides a solution/improvement which allows for adaptive learning for determining stimulation parameters for each individual patient beyond static programming. Therefore, a person of ordinary skill in the art would be motivated to improve the system of Bolea by incorporating the AI program for determining stimulation parameters via sensed data in Ahmad.
Therefore, Claim 23 is obvious over Bolea in view of Boggs, Scheiner, and Ahmad.
Regarding Claim 31, the method according to claim 30 is obvious over Bolea in view of Boggs and Scheiner, as indicated hereinabove. Bolea discloses:
• determining the tonal state of at least one of the genioglossus muscle or the geniohyoid muscle that form the protrusor muscles within the tongue of the patient based on the sensed EMG ([0231] – “the intramuscular or surface electrodes may be used to measure genioglossus EMG activity, either with or without stimulation”, [0042 and 0227] - Note a low muscle tonal state, which is corrected by stimulation to the protrusor muscles like the genioglossus muscle, would be associated with reduced patency and collapse of the upper airway);
• determining whether the apnea is likely to occur based on the one or more physiological parameters ([0161] - “Generally, the extracted 378 waveform and event data may be used for therapy tracking, for stimulus titration, and/or for closed loop therapy control. For example, data indicative of apneas and hypopneas (or other events) may be stored by the INS 50 and/or telemetered to the patient controlled 40 […] The data may also be used to control stimulus in a closed loop fashion by, for example, increasing stimulus intensity during periods of increased apnea and hypopnea occurrence or decreasing stimulus intensity during periods of decreased apnea and hypopnea occurrence.” The Examiner is interpreting this passage as relating to Bolea associating detection of apnea or hypopnea events with an increased likelihood of additional apnea and hypopnea events occurring over a timeframe (and which should be addressed with changes to stimulation parameters). Bolea additionally describes this stimulation as decreasing the likelihood of apnea or hypopnea events occurring in [0042]);
• determining the instance where (1) the tonal state of at least one of the genioglossus muscle or the geniohyoid muscle is the low tonal state, based on the sensed EMG ([0231] – genioglossus EMG activity measured, [0246] – the tonal state of the genioglossus or different muscles in the upper airway is assessed, along with sensing apnea/hypopnea, in order to determine the stimulation needed to establish patency), and (2) the apnea is likely to occur, based on the data collected by the sensor ([0161] - sensed data, such as the apnea hypopnea index derived from sensor outputs, is used to determine when an apnea event occurs); and
• controlling the timing of when the electrical energy is delivered to the one or more stimulation electrodes for delivery of the electrical energy based on the determined instance ([0242] – determination of stimulation pattern based on EMG feedback, [0161] – the determination of an apnea event, with physiologic parameters, can be used in closed-loop therapy stimulation control).
Bolea does not disclose an AI engine causing these functions.
Ahmad, in the same field of endeavor of stimulation of respiratory muscles during an apnea event ([0013]), teaches muscle tone via EMG or other physiologic parameters can be used to discern whether an apnea event is occurring ([0071]). The microprocessor can be used to apply stimulation upon detection and adjust stimulation intensity based on sensed data ([0131]). Ahmad also teaches the use of an AI engine to adjust stimulation based on inputs from sensors ([0100] – “Optionally, the therapeutic device and/or the associated external device will have self-learning capability to adjust stimulation levels and/or timing to the individual patient and the ambient”; [0186] – “The diagnostic and therapeutic devices are each a self-learning device uses artificial intelligence to adopt and adjust to the circumstances in which it is used. Each device adjusts itself to changes in the environmental conditions during the test as well as the changes in patient/user's conditions. Built in artificial intelligence also keeps tracks of the trends and historic values”).
It would have been obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to alter Bolea’s method for determining stimulation parameters via sensed data by incorporating the AI program for determining stimulation parameters via sensed data in Ahmad. This would have been obvious because both Bolea and Ahmad provide stimulation to improve airway patency during detected sleep apneas and Ahmad provides a solution/improvement which allows for adaptive learning for determining stimulation parameters for each individual patient beyond static programming. Therefore, a person of ordinary skill in the art would be motivated to improve the method of Bolea by incorporating the AI program for determining stimulation parameters via sensed data in Ahmad.
Therefore, Claim 31 is obvious over Bolea in view of Boggs, Scheiner, and Ahmad.
Conclusion
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Contact Information
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Benjamin Schmitt, whose telephone number is 703-756-1345. The examiner can normally be reached on Monday-Friday from 8:30 am to 5:00 pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer McDonald can be reached on 571-270-3061. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/Benjamin A. Schmitt/
Examiner
Art Unit 3796
/Jennifer Pitrak McDonald/Supervisory Patent Examiner, Art Unit 3796